The association between the serum 25-hydroxyvitamin D level and cardiovascular events in individuals with and without metabolic syndrome

  • 1Cardiologist, Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medicine Sciences, Isfahan, Iran.
  • 2Psychosomatic Research Center, Isfahan University of Medicine Sciences, Isfahan, Iran.
  • 3Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medicine Sciences, Isfahan, Iran.
  • 4Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medicine Sciences, Isfahan, Iran.
  • 5Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
  • 6Department of Neurology, Tehran University of Medical Sciences, Tehran, Iran AND Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL.
  • 7Professor, Department of Cardiology, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
  • 8Professor, Department of Cardiology, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
ARYA Atheroscler

Abstract

Background: Previous studies revealed that the level of 25-hydroxyvitamin D [25(OH)D] could be consider as one the risk factors for the occurrence of cardiovascular diseases (CVDs). This study aimed to evaluate the relationship between serum 25(OH)D level and CVD events in individuals with and without metabolic syndrome (MetS) in an Iranian population.

Methods: In this nested case-control study conducted as a part of the Isfahan Cohort Study (ISC), 55 patients with CVD events were selected as case group, and 55 sex- and age-matched individuals without CVD events as control group. These participants were divided into the two main groups based on the presence of MetS at baseline.

Results: The level of 25(OH)D in individuals with and without MetS was significantly lower among patients with CVD compared to those without CVD events at the baseline of study and after the follow-up (P = 0.036 and P = 0.039, respectively). The level of 25(OH)D significantly decreased risk of incidence of CVD events in individuals without MetS after adjusting for age, sex, nutrition, and exposure to sunlight [0.19 (0.05-0.73); P = 0.016]. There was not any significant relationship between the amount of 25(OH)D at the baseline and CVD events in individuals with MetS.

Conclusion: In individuals with MetS, the level of 25(OH)D is not related to CVD events; as MetS directly influence the pathophysiology of mechanisms which are responsible for CVD events, and maybe this effect obscure the effect of 25(OH)D.

Keywords: 25-Hydroxyvitamin D; Cardiovascular Diseases; Metabolic Syndrome.

How to Cite

Keivan Kiani, Hamidreza Roohafza, Mojgan Gharipour, Minoo Dianatkhah, Mohammad Talaei, Shahram Oveisgharan, Nizal Sarrafzadegan,and Masoumeh Sadeghi. The association between the serum 25-hydroxyvitamin D level and cardiovascular events in individuals with and without metabolic syndrome.ARYA Atheroscler
. 2018 Nov;14(6):254-259. doi: 10.22122/arya.v14i6.1703. PMID:31143226.